This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Single-Dose HPV Vaccine Evaluation Consortium

By Center for Vaccine Innovation and Access

Accumulating evidence suggests a single-dose of human papillomavirus (HPV) vaccine may elicit an immune response to protect against incident and persistent HPV infections, which are the necessary prerequisites to development of cervical lesions and in the longer term, cervical cancer.

Clinical trials, observational studies, and modeling analyses are ongoing to evaluate the efficacy, immunogenicity, effectiveness, and cost-effectiveness of single-dose HPV vaccination. Data accumulated to date provide strong evidence that a single-dose regimen could substantially reduce the incidence of HPV-attributable cervical precancer and cancer. Single-dose HPV vaccination could facilitate new options for current national programs by simplifying delivery and lowering program costs. For low- and middle-income countries that have delayed introducing HPV vaccines because of financial, logistical or other barriers; a single-dose HPV vaccination schedule could accelerate introduction of HPV vaccines into national immunization schedules.

The Single-Dose HPV Vaccine Evaluation Consortium encompasses eight leading independent research institutions working together to collate and synthesize existing evidence and evaluate new data on the potential for single-dose HPV vaccination. The consortium’s goal is to evaluate this evidence over the course of the project (2018–2022) to inform global policy discussions and program guidance, as well as to raise awareness and understanding of its implications.

Learn more about the consortium.

View PATH's resource on the evidence for and potential impact of a single-dose HPV vaccine regimen.

Publications on single-dose HPV vaccination